Literature DB >> 10574618

Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.

S Stürzebecher1, R Maibauer, A Heuner, K Beckmann, B Aufdembrinke.   

Abstract

In a study in 75 volunteers, preparations of interferon-beta1b (IFN-beta1b) and IFN-beta1a were compared in terms of the resulting serum concentrations of three biologic markers, neopterin, human Mx protein, and 2',5' oligoadenylate synthetase. Each preparation was tested at five dose levels, the middle dose being that recommended for use in patients with multiple sclerosis on the basis of large clinical trials. Five randomly chosen volunteers each received a single subcutaneous dose of one of the IFN or of IFN-beta1a given intramuscularly. The amounts of each marker induced were dose related. There were no major differences between the results with the two IFN or in the duration of the changes in the markers after the two routes of injection. The data indicated that 8 million international units (MIU) of IFN-beta1b and 6 MIU of IFN-beta1a had very similar effects. Even after the highest single dose tested, the increase in the biologic markers were not sustained for a full week.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574618     DOI: 10.1089/107999099312920

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  14 in total

Review 1.  Is multiple sclerosis a disease that requires frequent beta interferon dosing?

Authors:  Luca Durelli
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response.

Authors:  Douglas S Goodin
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Interferon-β-1b: a review of its use in multiple sclerosis.

Authors:  Greg L Plosker
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

4.  Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study.

Authors:  M Sandberg-Wollheim; C Bever; J Carter; M Färkkilä; B Hurwitz; Y Lapierre; P Chang; G S Francis
Journal:  J Neurol       Date:  2005-01       Impact factor: 4.849

Review 5.  The importance of maintaining effective therapy in multiple sclerosis.

Authors:  Luca Durelli; Marinella Clerico
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

Review 6.  Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

Authors:  D S Goodin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  Paul L McCormack; Lesley J Scott
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Dose and Frequency of Administration of Interferon-beta Affect its Efficacy in Multiple Sclerosis.

Authors:  Mohammed K Sharief
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 9.  Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.

Authors:  Joel P Thompson; Amir Abdolahi; Katia Noyes
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

10.  Excessive biologic response to IFNβ is associated with poor treatment response in patients with multiple sclerosis.

Authors:  Richard A Rudick; M R Sandhya Rani; Yaomin Xu; Jar-Chi Lee; Jie Na; Jennifer Shrock; Anupama Josyula; Elizabeth Fisher; Richard M Ransohoff
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.